-
Src Produits associés (225)
Produits associés (225)
-
TL02-59 dihydrochloride
0 ImagesCat. No.: HY-112852ACAS No.: 2415263-06-6
-
Tyrosine Kinase Peptide 1
0 ImagesCat. No.: HY-P2547CAS No.: 173691-86-6Tyrosine Kinase Peptide 1 is a control substrate peptide for c-Src assay.
-
Isomaltulose monohydrate
0 ImagesCat. No.: HY-W745090CAS No.: 58024-13-8Isomaltulose monohydrate is a fMLP inhibitor and also inhibits Src kinase, ERK1/2, p38 and AKT phosphorylation signals in immune regulation. Isomaltulose monohydrate can interfere with the interaction between the βγ subunit of the fMLP receptor Gi protein and its downstream molecules, thereby inhibiting fMLP-induced respiratory burst. Isomaltulose monohydrate inhibits fMLP (0.1 μM)-induced superoxide anion production (IC50: 1.98 μM) , cathepsin G release (IC< sub>50: 2.76 μM) and chemotaxis. Isomaltulose monohydrate can improve excessive activation of neutrophils and reduce inflammation or tissue damage. A series of derivatives of Isomaltulose monohydrate are found to have inhibitory effects on FSGS-related TRPC6 functional mutants.
-
5-POHSA
0 ImagesCat. No.: HY-W769935CAS No.: 2161370-68-75-POHSA is a CD36 and Src kinase modulator acting on taste bud cells, and belongs to the fatty acid esters of hydroxy fatty acids (FAHFA) family. 5-POHSA binds to lingual CD36 to initiate intracellular signaling pathways, activate downstream Src kinase, and rapidly elevate intracellular calcium levels. 5-POHSA interacts with the tongue-brain axis by binding to CD36, so as to ameliorate taste disorders and obesity-related adverse reactions. 5-POHSA is applicable to the research of obesity.
-
p60c-src Substrate
0 ImagesCat. No.: HY-P3743CAS No.: 165190-42-1p60c-src Substrate is an efficient and specific substrate for p60c-src protein tyrosine kinase (PTK). p60c-src Substrate can be used to synthesize chimeric branched peptides.
-
Dasatinib (GMP Like)
0 ImagesCat. No.: HY-10181GLCAS No.: 302962-49-8Synonyms: BMS-354825 (GMP Like)Dasatinib (GMP Like) (BMS-354825 (GMP Like)) is Dasatinib (HY-10181) produced by using GMP like guidelines. GMP Like small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. Dasatinib (BMS-354825) is a highly potent, ATP competitive, orally active dual Src/Bcr-Abl inhibitor with potent antitumor activity. The Kis are 16 pM and 30 pM for Src and Bcr-Abl, respectively. Dasatinib inhibits Bcr-Abl and Src with IC50s of <1.0 nM and 0.5 nM, respectively. Dasatinib also induces apoptosis and autophagy.
-
Caffeic acid-pYEEIE
0 ImagesCat. No.: HY-P1377CAS No.: 507471-72-9Caffeic acid-pYEEIE, a phosphopeptide inhibitor, exhibits potent binding affinity for the GST-Lck-SH2 domain.
-
(-)-Asarinin (Standard)
0 Images(-)-Asarinin (Standard) is the analytical standard of (-)-Asarinin (HY-N0701). This product is intended for research and analytical applications. (-)-Asarinin is a tetrahydrofurofurano lignan with various biological activities. (-)-Asarinin induces apoptosis in cancer cells. (-)-Asarinin promotes mitochondrial ROS accumulation, inhibits the STAT3 signaling pathway and induces apoptosis in precancerous cells. (-)-Asarinin is a Src family kinase inhibitor that suppresses mast cell activation. (-)-Asarinin is a non-competitive Δ5-desaturase inhibitor with a Ki of 0.28 mM. (-)-Asarinin possesses pain relief, anti-viral, anti-allergic and anti-tuberculous bacilli, and anti-tumor effects.
-
15-deoxy-Δ12,14-Prostaglandin D2-d4
0 ImagesCat. No.: HY-116028S1CAS No.: 2750534-91-7Synonyms: 15-Deoxy-Δ12,14-PGD2-d415-Deoxy-Δ12,14-Prostaglandin D2-d4 (15-Deoxy-Δ12,14-PGD2-d4) is the deuterium labeled 15-deoxy-Δ12,14-Prostaglandin D2. 15-deoxy-Δ12,14-Prostaglandin D2 (15-Deoxy-Δ12,14-PGD2) is a metabolite of prostaglandin D₂ (PGD₂) (HY-101988), which can undergo further dehydration metabolism to 15-deoxy-Δ12,14-PGJ₂. 15-deoxy-Δ12,14-Prostaglandin D2 is a highly selective agonist for DP2 receptor and PPARγ. 15-deoxy-Δ12,14-Prostaglandin D2 causes morphological changes in eosinophils and migration of type II innate lymphoid cells (ILC2). 15-deoxy-Δ12,14-Prostaglandin D2 has a growth inhibitory effect on prostate cancer cells expressing PPARγ, induces cell cycle arrest and promotes apoptosis. 15-deoxy-Δ12,14-Prostaglandin D2 can be used in related research on asthma and prostate cancer.
-
CGP77675 hydrate
0 ImagesCat. No.: HY-W062835ACGP77675 hydrate is an orally active and potent inhibitor of Src family kinases. CGP77675 hydrate inhibits phosphorylation of peptide substrates and autophosphorylation of purified Src (IC50s of 5-20 and 40 nM, respectively),and also inhibits Src, EGFR, KDR, v-Abl, and Lck with IC50s of 0.02, 0.15, 1.0, 0.31, and 0.29 μM, respectively. Anticancer activity.
-
PROTAC DDa-1
0 ImagesCat. No.: HY-156745CAS No.: 3036944-98-3PROTAC DDa-1 is a multi-targeted DCAF1-recruiting tyrosine kinase PROTAC degrader. PROTAC DDa-1 mediates the degradation of TNK2, CSK, LIMK2, TEC, and BTK, with a DC50 of 90 nM for BTK. PROTAC DDa-1 reduces the viability of BTK-dependent diffuse large B-cell lymphoma cells. PROTAC DDa-1 can be used for the research of diffuse large B-cell lymphoma.
-
Cisplatin/Dasatinib prodrug-1
0 ImagesCat. No.: HY-161687CAS No.: 3049801-09-1Cisplatin/Dasatinib prodrug-1 (Compound 3) is a prodrug of Cisplatin (HY-17394) and Dasatinib (HY-10181). Cisplatin/Dasatinib prodrug-1 exhibits antiproliferative activity against A2780, MDA-MB-231, MCF7, HCT116, RD, Thp1 and HL60 cancer cells with IC50s of 0.1, 0.1, 0.36, 2.0, 0.4, 0.3 and 0.25 μM, respectively.
-
RR-SRC
0 ImagesCat. No.: HY-P0200CAS No.: 81156-93-6RR-SRC is a substrate for src-tyrosine-specific protein kinase.
-
N-Acetyl-O-phosphono-Tyr-Glu dipentylamide
0 ImagesCat. No.: HY-108487CAS No.: 190078-50-3Synonyms: Ac-Tyr-Glu-N(n-C5H11)2N-Acetyl-O-phosphono-Tyr-Glu dipentylamide (Ac-Tyr-Glu-N(n-C5H11)2), a dipeptide, is a pp60c-src SH2 domain inhibitor. N-Acetyl-O-phosphono-Tyr-Glu dipentylamide can be used for cancer research.
-
Birelentinib
0 ImagesCat. No.: HY-160167CAS No.: 2662512-15-2Synonyms: DZD8586Birelentinib (DZD8586) is an orally effective, selective, non-covalent inhibitor targeting LYN tyrosine kinase and BTK tyrosine kinase, capable of penetrating the blood-brain barrier. Birelentinib exhibits concentration-dependent antiproliferative effects in RI-1 cells and diffuse large B-cell lymphoma (DLBCL) cell lines carrying BTK resistance mutations (such as C481X, V416L, etc.). Birelentinib blocks both BTK-dependent and independent signaling of the B-cell receptor (BCR), thereby inhibiting tumor cell proliferation and inducing cell death. Birelentinib can be used in research to overcome resistance to existing covalent and non-covalent BTK inhibitors in B-cell non-Hodgkin lymphoma (B-NHL).
